Malignant Glioma Research Update
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Malignant Glioma: A diagnosis your patient wants do not want to receive. As their primary physician what more can you tell your patient? What does the latest research indicate about the pathobiology of Gliomas? In this segment our guest Dr. Mitchel Berger, Professor and Chair of Neurological Surgery at the University of California, San Francisco, talks with host Dr. Bill Rutenberg about the latest Glioma research. They discuss the genetic advances that may lead to new treatments including a possible vaccination currently being developed that could one day replace mainstay treatments including radiation and chemotherapy.
Overview
Malignant Glioma: A diagnosis your patient wants do not want to receive. As their primary physician what more can you tell your patient? What does the latest research indicate about the pathobiology of Gliomas? In this segment our guest Dr. Mitchel Berger, Professor and Chair of Neurological Surgery at the University of California, San Francisco, talks with host Dr. Bill Rutenberg about the latest Glioma research. They discuss the genetic advances that may lead to new treatments including a possible vaccination currently being developed that could one day replace mainstay treatments including radiation and chemotherapy.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
HF Management for Patients with Comorbid Conditions
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
Second-line Chemotherapy Options in Metastatic PDAC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?